ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 02 Jan 2024
A- A+
Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours Guidance is outdated and has been withdrawn on 2 Jan 2024. 

The Plain English Summary (PES) has been updated on 2 Jan 2024.  Everolimus, lanreotide, octreotide and sunitinb for treating advanced neuroendocrine tumours (Withdrawn 2 Jan 2024) PES Treatments for advanced neuroendocrine tumours (Updated 2 Jan 2024)